Skip to content

Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study

Official Full-Text Publication: Ustekinumab in nail psoriasis: An open-label, uncontrolled, nonrandomized study on ResearchGate, the professional network for scientists. Methods: Twenty-seven patients suffering from moderate-to-severe plaque psoriasis with nail involvement were enrolled in this open-label, uncontrolled, nonrandomized study to evaluate the therapeutic potential of ustekinumab. Participants were scheduled to receive subcutaneous injections of ustekinumab at a dose of 45 mg at baseline and week 4 and every 12 weeks thereafter. METHODS: Twenty-seven patients suffering from moderate-to-severe plaque psoriasis with nail involvement were enrolled in this open-label, uncontrolled, nonrandomized study to evaluate the therapeutic potential of ustekinumab.

Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study 2Nail psoriasis results from psoriatic involvement of the nail bed or nail matrix.Patients with nail psoriasis can develop a wide variety of nail ch. Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. Nail psoriasis can be treated effectively using topical treatments, intralesional treatments, and systemic treatments, but an optimal effect may take up to 1 year. Another open-label, uncontrolled study of ustekinumab in nail psoriasis confirmed these excellent results 148. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. Phase III clinical trials of infliximab3, ustekinumab4, and adalimumab5 have reported nail psoriasis improvements. Patsatsi A, Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.

Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study, Journal of Dermatological Treatment. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat. J Dermatolog Treat 2013 Apr 8;24(2):96-100. Induced Paradoxical Psoriasis Flare in a Patient with Psoriatic Arthritis: Case Report and Review. Case Report: We report on a 47-year-old woman who developed incapacitating palmoplantar pustulosis and psoriasis vulgaris flare with severe scalp and nail involvement after 5 months of treatment with adalimumab for psoriatic arthritis.

Nail Psoriasis

Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J. Dermatol. Treat. 24:96100. 36. Rigopoulos D, Gregoriou S, Makris M, Ioannides D. 2011. Efficacy of ustekinumab in nail psoriasis and. Velden H.M., Klaassen K.M., van de Kerkhof P.C., Pasch M.C. Fingernail psoriasis reconsidered: a case-control study. Kyriakou A, Sotiriadis D. Ustekinumab in nail psoriasis: An open-label, uncontrolled, nonrandomized study. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients. Soo Hyun Lee, Seong Ho Wee, Hyung-Joo Kim, Un-Cheol Yeo, Nam Ho Lee, Se Won Lee, Sung Bin Cho. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. Aikaterini Patsatsi, Aikaterini Kyriakou, Dimitrios Sotiriadis. A Randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept; Lynde CW, Gupta A et al. Ustekinumab in nail psoriasis: an open label, uncontrolled, nonrandomized study; Patsatsi A, Kyriakou A et al.; The vexing problems of when, where, and how to biopsy the nail matrix for longitudinal melanonychia and other nail tumors will be explored. Psoralen plus ultraviolet A (PUVA) and Grenz ray treatments have both demonstrated temporary benefits in uncontrolled studies of nail psoriasis. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis.

Challenging Regional Psoriasis And Ustekinumab Biotherapy: Impact Of The Patterns Of Disease